Sanofi

Missing the #Paris2024 Olympic & Paralympic Games? So are we! 🥹 Relive the magic of the Games with our behind-the-scenes documentary celebrating everything we achieved together through our partnership with Paris 2024. From high-fives to the teary-eyed, this film captures it all through the eyes of Sanofians: our volunteers on their mission, our torchbearers on their journey and the team who planned it, lived it and will never forget it. While the Games may be over for another four years, this journey has ignited our ambition to look beyond what we once thought was impossible. 🎬 Watch the full video here: http://spkl.io/6045fnnJb #WeNeverSettle #IgnitingPotential

The burden of COPD goes beyond just lung function. COPD is a debilitating and devastating disease that often can make it difficult for people to live the life that they want. This #WorldCOPDDay, we join Manuela Buxo in recognizing the resilience of those living with #COPD and reaffirm our commitment to standing with the COPD community and caregivers every step of the way. https://lnkd.in/eEwVyDF8

We’re thrilled to be ranked #3 in the 2024 Access to Medicine Index and recognized as one of the top risers this year! 🌍 This achievement reflects our efforts on access planning for projects in our R&D pipeline and the impactful work of our Global Health Unit. Launched in 2021, our Global Health Unit is driving improved product access in LMICs, fostering partnerships, and championing an inclusive business model recognized as a “Best Practice” in the industry by the Access to Medicine Foundation. Discover how we’re advancing global health 👉 http://spkl.io/6043fVLPN #ATMI24 #AccessToMedicine #HealthcareAccess

Today the FDA accepted the resubmission of our application for an investigational medicine for chronic spontaneous urticaria (CSU), an inflammatory skin disease driven in part by type 2 inflammation. We remain committed to bringing a new option for people suffering from this condition which causes sudden and debilitating hives and recurring itch. Learn more: http://spkl.io/6042fVJ2E Regeneron

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) recommended the approval of our #MultipleMyeloma combination therapy. If approved, this would be the first therapy in its class available in the EU, in combination with a current standard-of-care regimen, for newly diagnosed multiple myeloma patients who are transplant-ineligible. Read our press release: https://lnkd.in/dnp6T5eM

Today is #WorldDiabetesDay. 💙 We join the global community to raise awareness about this global health challenge. Empowering healthcare professionals is essential to positively impact the well-being of people with #diabetes, especially in low- and middle-income countries. Our Global Health Unit partners with International Diabetes Federation to provide online training in 40 countries which has benefited over 1,450 healthcare professionals to-date. Learn more: http://spkl.io/6044fpsRA #Sanofi #GlobalHealth #Impact #SocialImpact #DiabetesLife

How can we harness the immune system to fight type 1 #diabetes? Learn more about how Sanofi is using immunoscience to develop new treatments that stop the immune system from attacking insulin-producing cells, possibly before T1D symptoms even appear: http://spkl.io/6043fpseU

With the power of #AI, we’re discovering new ways to effectively harness the immune system and accelerate the development of new treatments for complex diseases. In a recent article published in WIRED, our visionary R&D leaders - Houman Ashrafian, Emmanuel Frenehard, and Helen Merianos - share how our approach to AI-powered immunoscience could unlock new possibilities in healthcare and deliver potentially life-changing therapies to patients faster than ever before. Read the article to learn more 👉 http://spkl.io/6049frdJZ #TransformingCare #Immunoscience

From asthma to COPD, allergies to other inflammatory conditions, the impacts of climate change on immune-driven diseases are evident. In a new Project Syndicate article, our CEO Paul Hudson discusses how global warming is increasing the prevalence and exacerbation of respiratory diseases and shares insights on strategies to help address the consequences suffered by the most vulnerable populations. Read more: http://spkl.io/6044fTlli #ClimateChange #AI

The European Commission has approved the first and only medicine for children aged 1-11 with eosinophilic esophagitis (#EoE). We’re proud to offer a treatment option that has the potential to improve the standard of care for children living with this chronic, progressive disease. Learn more about the news: https://lnkd.in/eUtjGA3b    Regeneron